세계의 고면역글로불린 시장 보고서(2025년)
Hyperimmune Globulins Global Market Report 2025
상품코드 : 1825770
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

고면역글로불린 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.1%로 27억 1,000만 달러로 성장할 것입니다. 예측 기간의 성장은 감염성 질환의 유행 증가, 고면역글로불린 주사의 이점에 대한 인식 증가, 면역글로불린에 대한 수요 증가, α-1 항트립신 결핍증의 유행 증가, 면역부전 발생률 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 기술 발전과 혁신, 연구개발 투자, 수동 면역치료에 대한 수요, 혈장 유래 치료의 발전, 제조기술의 발전 등을 꼽을 수 있습니다.

향후 5년간 7.1%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 오스트리아와 브라질에서 조달되는 광견병과 파상풍의 비용을 상승시키고, 노출 후 예방을 지연시키거나 응급 의료 비용을 상승시킬 수 있기 때문에 미국의 전염병 관리에 혼란을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

고면역글로불린 시장은 감염성 질환의 증가로 인해 성장할 것으로 보입니다. 바이러스, 세균, 곰팡이, 기생충 등의 병원체에 의해 발생하는 이러한 질병은 항균제 내성, 기후변화, 인구 증가 등의 요인으로 인해 증가 추세에 있습니다. 고면역글로불린은 특정 병원체를 표적으로 하는 농축 항체를 통해 즉각적인 수동 면역을 제공함으로써 감염과 싸우는 데 중요한 역할을 합니다. 이는 2021-2022년 사이 미국에서 환자 수가 17% 증가한 만성 B형 간염 등의 사례에서 볼 수 있듯이 질병의 예방과 치료에 도움이 됩니다. 따라서 감염성 질환의 증가는 고면역글로불린 시장에 직접적인 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Hyperimmune globulins are specialized preparations of antibodies enriched with specific antibodies against a particular pathogen or antigen. These preparations are obtained from the plasma of individuals who have high levels of antibodies against a specific infectious agent or toxin. They are utilized for passive immunization to confer immediate immunity against certain diseases, particularly in situations requiring prompt protection.

The primary types of hyperimmune globulins include hepatitis B hyperimmune globulin, rabies hyperimmune globulin, tetanus hyperimmune globulin, cytomegalovirus (CMV) hyperimmune globulin, varicella-zoster virus (VZV) hyperimmune globulin, respiratory syncytial virus (RSV) hyperimmune globulin, among others. Hepatitis B hyperimmune globulin, for example, is derived from the plasma of donors with high antibody titers against the hepatitis B virus. These preparations are administered via various routes such as intramuscular or intravenous, serving diverse applications across governmental, private, and other sectors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hyperImmune globulin market research report is one of a series of new reports from The Business Research Company that provides hyperImmune globulin market statistics, including hyperImmune globulins industry global market size, regional shares, competitors with a hyperImmune globulin market share, detailed hyperImmune globulin market segments, market trends, and opportunities, and any further data you may need to thrive in the hyperImmune globulins industry. This hyperImmune globulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperimmune globulins market size has grown strongly in recent years. It will grow from $1.91 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increased government support, rise in healthcare expenditures.

The hyperimmune globulins market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to the increasing prevalence of infectious diseases, growing awareness about the benefits of hyperimmune globulin injections, increasing demand for immunoglobulins, rising prevalence of alpha-1 antitrypsin deficiency, rising incidence of immune deficiencies. Major trends in the forecast period include technological advancements and innovation, investment in research and development, demand for passive immunity treatments, advancements in plasma-derived therapies, and technological advancements in manufacturing.

The forecast of 7.1% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. infectious disease control by increasing costs for rabies and tetanus hyperimmune globulins sourced from Austria and Brazil, potentially delaying post-exposure prophylaxis and raising emergency care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The hyperimmune globulin market is set to grow due to the increasing prevalence of infectious diseases. These diseases, caused by pathogens such as viruses, bacteria, fungi, and parasites, are on the rise due to factors such as antimicrobial resistance, climate change, and population growth. Hyperimmune globulins play a crucial role in combating infectious diseases by providing immediate passive immunity through concentrated antibodies targeting specific pathogens. This aids in disease prevention or treatment, as seen in cases such as chronic hepatitis B, where the number of cases in the US increased by 17% from 2021 to 2022. Therefore, the growth of infectious diseases is directly impacting the hyperimmune globulin market.

Government efforts to advance healthcare research and development are poised to boost the hyperimmune globulins market in the coming years. These initiatives are escalating due to growing demand for innovative medical solutions and the necessity to confront emerging health issues. They play a crucial role in fostering the development and accessibility of hyperimmune globulins, particularly in combating specific infectious diseases effectively. For example, in 2022, the UK government allocated £260 million (US $270.65 million) through the Business, Energy, and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC) to enhance healthcare research and manufacturing. This funding supports NHS-led health research, new privacy-preserving platforms for diagnostics and treatment, clinical research services, and also includes £60 million (US $63.60 million) to bolster life sciences manufacturing in the UK. Therefore, the increasing government focus on healthcare research and development is a key driver of the hyperimmune globulins market.

In April 2022, Grifols S.A., a pharmaceutical company based in Spain, acquired Biotest for an undisclosed sum. This acquisition positions Grifols to enhance and diversify its product portfolio, increase the availability of plasma therapies, operate the largest private European network of plasma centers with 87 centers, and stimulate revenue growth and margin expansion. Biotest, a biotechnology company based in Germany, specializes in hyperimmune globulins, which aligns with Grifols' strategic goals.

Major companies operating in the hyperimmune globulins market are F. Hoffmann-La Roche AG, Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., FFF Enterprises Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Omrix Biopharmaceuticals Ltd., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., BioCare Inc.

North America was the largest region in the hyperimmune globulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hyperimmune globulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperimmune globulins market consists of sales of bayrab, hepaGam B, Tetanus Immune Globulin (TIG), variZIG, respiGam, and cytogam. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hyperimmune Globulins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperimmune globulins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hyperimmune globulins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hyperimmune globulins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hyperimmune Globulins Market Characteristics

3. Hyperimmune Globulins Market Trends And Strategies

4. Hyperimmune Globulins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hyperimmune Globulins Growth Analysis And Strategic Analysis Framework

6. Hyperimmune Globulins Market Segmentation

7. Hyperimmune Globulins Market Regional And Country Analysis

8. Asia-Pacific Hyperimmune Globulins Market

9. China Hyperimmune Globulins Market

10. India Hyperimmune Globulins Market

11. Japan Hyperimmune Globulins Market

12. Australia Hyperimmune Globulins Market

13. Indonesia Hyperimmune Globulins Market

14. South Korea Hyperimmune Globulins Market

15. Western Europe Hyperimmune Globulins Market

16. UK Hyperimmune Globulins Market

17. Germany Hyperimmune Globulins Market

18. France Hyperimmune Globulins Market

19. Italy Hyperimmune Globulins Market

20. Spain Hyperimmune Globulins Market

21. Eastern Europe Hyperimmune Globulins Market

22. Russia Hyperimmune Globulins Market

23. North America Hyperimmune Globulins Market

24. USA Hyperimmune Globulins Market

25. Canada Hyperimmune Globulins Market

26. South America Hyperimmune Globulins Market

27. Brazil Hyperimmune Globulins Market

28. Middle East Hyperimmune Globulins Market

29. Africa Hyperimmune Globulins Market

30. Hyperimmune Globulins Market Competitive Landscape And Company Profiles

31. Hyperimmune Globulins Market Other Major And Innovative Companies

32. Global Hyperimmune Globulins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hyperimmune Globulins Market

34. Recent Developments In The Hyperimmune Globulins Market

35. Hyperimmune Globulins Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기